April 9, 2025—Chen Zhijie, Member of the Standing Committee of the Hechi Municipal Committee of the CPC, Member of the Leading Party Members Group of the Hechi Municipal Government, and Vice Mayor of Hechi City, along with a delegation, visited Tianming Pharmaceutical’s Jinan R&D Center for an inspection and exchange.
Li Gang, Chairman of Tianming Pharmaceutical, led the company’s team in receiving the delegation. The two sides engaged in discussions on pharmaceutical industry innovation and regional cooperation.
Accompanied by Li Gang, the delegation toured the Pharma Valley Industrial Park, where staff from the Life Science City introduced Jinan’s development plans for the healthcare industry. Subsequently, the delegation visited the company’s R&D center.
Li Gang guided the delegation through the facilities and elaborated on Tianming Pharmaceutical Group’s growth trajectory.
Vice Mayor Chen Zhijie spoke highly of Tianming Pharmaceutical’s R&D capabilities, highlighting that Hechi City is actively promoting the clustered development of its biopharmaceutical industry and that Tianming’s experience offers valuable insights.
Qing Hongjun, Director of the Hechi Municipal Development and Reform Commission, inquired in detail about the operations of the company’s production base in Hechi, Guangxi, and affirmed the effectiveness of the collaborative model integrating “Jinan R&D + Hechi production.”
During the symposium, Chairman Li Gang shared Tianming Pharmaceutical’s strategic initiatives, emphasizing the group’s ongoing digital transformation initiatives. He introduced the construction of Guangxi’s GMP-compliant workshops and hydrogenation facilities, which adhere to advanced industry standards to ensure product quality meets international benchmarks. He also noted the company’s partnerships with leading domestic and international pharmaceutical enterprises.
Lu Rong, Secretary-General of the Hechi Municipal Government, elaborated on the city’s industrial policies, stating that Hechi is leveraging reforms in industrial park management to optimize its business environment and provide one-stop services for biopharmaceutical enterprises.
Li Gang, Chairman of Shandong Tianming, expressed gratitude for the visit by Hechi’s leadership. He stated that Tianming Pharmaceutical will seize the opportunity presented by this exchange to advance the modernization of Guangxi Tianming’s industrial base under the coordinated planning and policy guidance of the Hechi Municipal People’s Government.
The company will prioritize establishing an industry-academia-research collaborative innovation center and drive the upgrade of Hechi’s healthcare industry cluster through intelligent and green development strategies.
Comparing Nifedipine & Amlodipine: Onset, duration, and side effects decoded. Demand for amlodipine intermediates? We deliver quality.
Hechi Vice Mayor Chen Zhijie toured Tianming Pharmaceutical’s facilities, praising its R&D strength and the “Jinan R&D + Hechi production” model.
This non-peptide GLP-1 receptor agonist, now in late-stage clinical trials, is redefining possibilities for diabetes and obesity treatment. Let’s unpack what makes it distinctive from both lab bench and manufacturing perspectives.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.